G
Giovanni Martinelli
Researcher at University of Bologna
Publications - 1323
Citations - 52138
Giovanni Martinelli is an academic researcher from University of Bologna. The author has contributed to research in topics: Myeloid leukemia & Imatinib mesylate. The author has an hindex of 99, co-authored 1233 publications receiving 45436 citations. Previous affiliations of Giovanni Martinelli include University of Naples Federico II & University of Milan.
Papers
More filters
Journal ArticleDOI
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Journal ArticleDOI
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy P. Hughes,Michael W. Deininger,Andreas Hochhaus,Susan Branford,Jerald P. Radich,Jaspal Kaeda,Michele Baccarani,Jorge E. Cortes,Nicholas C.P. Cross,Brian J. Druker,Jean Gabert,David Grimwade,Rüdiger Hehlmann,Suzanne Kamel-Reid,Jeffrey H. Lipton,Janina A. Longtine,Giovanni Martinelli,Giuseppe Saglio,Simona Soverini,Wendy Stock,John M. Goldman +20 more
TL;DR: Suggestions are made for harmonizing the differing methodologies for measuring BCR-ABL transcripts in patients with CML undergoing treatment and using a conversion factor whereby individual laboratories can express BCR -ABL transcript levels on an internationally agreed scale.
Journal ArticleDOI
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Hagop M. Kantarjian,Daniel J. DeAngelo,Matthias Stelljes,Giovanni Martinelli,Michaela Liedtke,Wendy Stock,Nicola Gökbuget,Susan O'Brien,Kongming Wang,Tao Wang,M. Luisa Paccagnella,Barbara Sleight,Erik Vandendries,Anjali S. Advani +13 more
TL;DR: The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy, and a higher percentage of patients in the inotzumabozogamic in group had results below the threshold for minimal residual disease.
Journal ArticleDOI
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Hervé Dombret,John F. Seymour,Aleksandra Butrym,Agnieszka Wierzbowska,Dominik Selleslag,Jun Ho Jang,Rajat Kumar,James Cavenagh,Andre C. Schuh,Anna Candoni,Christian Recher,Irwindeep Sandhu,Teresa Bernal del Castillo,Haifa Kathrin Al-Ali,Giovanni Martinelli,Jose F Falantes,Richard Noppeney,Richard Stone,Mark D. Minden,Heidi McIntyre,S. Songer,Lela M. Lucy,C.L. Beach,Hartmut Döhner +23 more
TL;DR: Univariate analysis showed favorable trends for azacitidine compared with CCR across all subgroups defined by baseline demographic and disease features, and adverse events were consistent with the well-established safety profile of azacItidine.
Journal ArticleDOI
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
Daniela Cardinale,Alessandro Colombo,Maria T. Sandri,Giuseppina Lamantia,Nicola Colombo,Maurizio Civelli,Giovanni Martinelli,Fabrizio Veglia,Cesare Fiorentini,Carlo M. Cipolla +9 more
TL;DR: In high-risk, HDC-treated patients, defined by an increased troponin I value, early treatment with enalapril seems to prevent the development of late cardiotoxicity.